MX2020004972A - Uso de compuesto de carbamato para prevenir, aliviar o tratar ataque de ausencia o epilepsia que muestra ataque de ausencia. - Google Patents

Uso de compuesto de carbamato para prevenir, aliviar o tratar ataque de ausencia o epilepsia que muestra ataque de ausencia.

Info

Publication number
MX2020004972A
MX2020004972A MX2020004972A MX2020004972A MX2020004972A MX 2020004972 A MX2020004972 A MX 2020004972A MX 2020004972 A MX2020004972 A MX 2020004972A MX 2020004972 A MX2020004972 A MX 2020004972A MX 2020004972 A MX2020004972 A MX 2020004972A
Authority
MX
Mexico
Prior art keywords
absence seizure
alleviating
preventing
treating
carbamate compound
Prior art date
Application number
MX2020004972A
Other languages
English (en)
Spanish (es)
Inventor
Hye Won Shin
Original Assignee
Sk Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=66540315&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2020004972(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sk Biopharmaceuticals Co Ltd filed Critical Sk Biopharmaceuticals Co Ltd
Publication of MX2020004972A publication Critical patent/MX2020004972A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
MX2020004972A 2017-11-14 2018-11-13 Uso de compuesto de carbamato para prevenir, aliviar o tratar ataque de ausencia o epilepsia que muestra ataque de ausencia. MX2020004972A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170151248 2017-11-14
PCT/KR2018/013761 WO2019098628A1 (ko) 2017-11-14 2018-11-13 결신 발작 또는 결신 발작을 나타내는 뇌전증의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도

Publications (1)

Publication Number Publication Date
MX2020004972A true MX2020004972A (es) 2020-08-24

Family

ID=66540315

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020004972A MX2020004972A (es) 2017-11-14 2018-11-13 Uso de compuesto de carbamato para prevenir, aliviar o tratar ataque de ausencia o epilepsia que muestra ataque de ausencia.

Country Status (16)

Country Link
US (1) US20200352907A1 (https=)
EP (1) EP3711758B1 (https=)
JP (2) JP7258901B2 (https=)
KR (1) KR102739584B1 (https=)
CN (1) CN111432812A (https=)
AU (1) AU2018367729B2 (https=)
BR (1) BR112020009265A2 (https=)
CA (1) CA3081223A1 (https=)
DK (1) DK3711758T3 (https=)
ES (1) ES2982316T3 (https=)
FI (1) FI3711758T3 (https=)
IL (1) IL274428B2 (https=)
MX (1) MX2020004972A (https=)
PL (1) PL3711758T3 (https=)
PT (1) PT3711758T (https=)
WO (1) WO2019098628A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3854392A4 (en) * 2018-09-21 2022-08-17 SK Biopharmaceuticals Co., Ltd. USE OF A CARBAMATE COMPOUND TO PREVENT, RELIEVE OR TREAT CONJUNCTING SEIGES
CN116143717B (zh) * 2021-11-22 2025-05-06 康百达(四川)生物医药科技有限公司 一种氘代氨基甲酸酯化合物及其在医药上的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6383764B1 (en) 2000-04-28 2002-05-07 The Regents Of The University Of California Methods of identifying compounds for controlling absence seizures in a mammal relating to prolactin-releasing peptide(PrRP)
KR100534556B1 (ko) 2001-10-26 2005-12-08 주식회사 오리엔트바이오 알파1g 단백질의 기능을 억제하여 간질을 일으키지 않게하는 방법
EP1707204A1 (en) * 2005-04-01 2006-10-04 Bioprojet Treatment of epilepsy with non-imidazole alkylamines histamine H3-receptor ligands
US7598279B2 (en) * 2005-04-22 2009-10-06 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
WO2010150946A1 (en) * 2009-06-22 2010-12-29 Sk Holdings Co., Ltd. Method for preparation of carbamic acid (r)-1-aryl-2-tetrazolyl-ethyl ester
US8404461B2 (en) * 2009-10-15 2013-03-26 SK Biopharmaceutical Co. Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
US9629853B2 (en) 2014-05-21 2017-04-25 Wisconsin Alumni Research Foundation Uses of ganaxolone
KR102489052B1 (ko) 2016-05-19 2023-01-16 에스케이바이오팜 주식회사 섬유근육통 또는 섬유근육통의 연관된 기능적 증후군을 예방 또는 치료하기 위한 카바메이트 화합물의 용도
CA3046458A1 (en) 2016-12-14 2018-06-21 Sk Biopharmaceuticals Co., Ltd. Parenteral liquid preparation comprising carbamate compound
WO2019045121A1 (en) 2017-08-31 2019-03-07 Takeda Pharmaceutical Company Limited TREATMENT OF CNS DISEASES

Also Published As

Publication number Publication date
ES2982316T3 (es) 2024-10-15
CN111432812A (zh) 2020-07-17
KR102739584B1 (ko) 2024-12-06
CA3081223A1 (en) 2019-05-23
JP7578747B2 (ja) 2024-11-06
BR112020009265A2 (pt) 2020-10-20
AU2018367729A1 (en) 2020-05-21
IL274428A (en) 2020-06-30
IL274428B2 (en) 2023-08-01
JP7258901B2 (ja) 2023-04-17
JP2023085469A (ja) 2023-06-20
JP2021503010A (ja) 2021-02-04
KR20200074153A (ko) 2020-06-24
RU2020119292A3 (https=) 2022-02-24
EP3711758A4 (en) 2021-08-04
AU2018367729B2 (en) 2024-06-13
PT3711758T (pt) 2024-04-22
US20200352907A1 (en) 2020-11-12
EP3711758B1 (en) 2024-03-27
DK3711758T3 (da) 2024-04-08
RU2020119292A (ru) 2021-12-15
EP3711758A1 (en) 2020-09-23
PL3711758T3 (pl) 2024-07-01
WO2019098628A1 (ko) 2019-05-23
IL274428B1 (en) 2023-04-01
FI3711758T3 (fi) 2024-05-13

Similar Documents

Publication Publication Date Title
PH12020551014A1 (en) Amino-fluoropiperidine derivatives as kinase inhibitor
PH12020551013A1 (en) Oxy-fluoropiperidine derivative as kinase inhibitor
PH12020500673A1 (en) Compounds
PH12019500480A1 (en) Pyridine compound
SA520411524B1 (ar) مركبات تنشيط القسيم العضلي ثنائي الأميد واستخداماتها
PH12015502031B1 (en) Tetrahydropyrrolothiazine compounds
PH12020550993A1 (en) Amino-methyl piperidine derivative as kinase inhibitor
PH12020551586A1 (en) Oxysterols and methods of use thereof
PH12016501517A1 (en) Tetrazolone-substituted dihydropyridinone mgat2 inhibitors
PH12019500370A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
MX2019001228A (es) Metodo de produccion del compuesto de pirazol-amida.
MX2020004974A (es) Uso del compuesto de carbamato para reducir o tratar trastornos del desarrollo que incluyen sindrome x fragil, sindrome de angelman o sindrome de rett.
PH12019502046A1 (en) Pyrrolotriazine derivatives as kinase inhibitor
MY193239A (en) Novel b-lactamase inhibitors
PH12018500999A1 (en) Sodium channel blocker
PH12019550154A1 (en) Azetidine derivative
PH12017501404A1 (en) Diaza-benzofluoranthrene compounds
MX2020004972A (es) Uso de compuesto de carbamato para prevenir, aliviar o tratar ataque de ausencia o epilepsia que muestra ataque de ausencia.
PH12018501100A1 (en) Phenylimidazole compound
NZ748746A (en) Pyrazolopyrimidine derivatives as kinase inhibitor
SA119400353B1 (ar) مشتق بيرازول مستبدل